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Abstract
Objective To quantify the overall effects of bariatric surgery compared
with non-surgical treatment for obesity.
Design Systematic review andmeta-analysis based on a random effects
model.
Data sources Searches of Medline, Embase, and theCochrane Library
from their inception to December 2012 regardless of language or
publication status.
Eligibility criteria Eligible studies were randomised controlled trials with
≥6 months of follow-up that included individuals with a body mass index
≥30, compared current bariatric surgery techniques with non-surgical
treatment, and reported on body weight, cardiovascular risk factors,
quality of life, or adverse events.
Results The meta-analysis included 11 studies with 796 individuals
(range of mean bodymass index at baseline 30-52). Individuals allocated
to bariatric surgery lost more body weight (mean difference −26 kg (95%
confidence interval −31 to −21)) compared with non-surgical treatment,
had a higher remission rate of type 2 diabetes (relative risk 22.1 (3.2 to
154.3) in a complete case analysis; 5.3 (1.8 to 15.8) in a conservative
analysis assuming diabetes remission in all non-surgically treated
individuals with missing data) and metabolic syndrome (relative risk 2.4
(1.6 to 3.6) in complete case analysis; 1.5 (0.9 to 2.3) in conservative
analysis), greater improvements in quality of life and reductions in
medicine use (no pooled data). Plasma triglyceride concentrations
decreased more (mean difference −0.7 mmol/L (−1.0 to −0.4) and high
density lipoprotein cholesterol concentrations increased more (mean
difference 0.21 mmol/L (0.1 to 0.3)). Changes in blood pressure and
total or low density lipoprotein cholesterol concentrations were not
significantly different. There were no cardiovascular events or deaths
reported after bariatric surgery. The most common adverse events after
bariatric surgery were iron deficiency anaemia (15% of individuals
undergoing malabsorptive bariatric surgery) and reoperations (8%).
ConclusionsCompared with non-surgical treatment of obesity, bariatric
surgery leads to greater body weight loss and higher remission rates of
type 2 diabetes and metabolic syndrome. However, results are limited
to two years of follow-up and based on a small number of studies and
individuals.
Systematic review registrationPROSPEROCRD42012003317 (www.
crd.york.ac.uk/PROSPERO).
Introduction
Obesity is one of the greatest public health problems in
industrialised countries.1 2 In the US, UK, and Australia, for
instance, the prevalence of obesity (body mass index (weight
(kg)/(height (m)2) >30) has more than doubled in the past 25
years.2Currently, 67% of the US population is either overweight
or obese, and in most European countries the prevalence ranges
between 40% and 50%.3Obesity is associated with an increased
risk for type 2 diabetes, hypertension, dyslipidaemia,
cardiovascular diseases, musculoskeletal disorders (such as
osteoarthritis), certain types of cancer, and mortality.4 This
entails huge healthcare costs due to obesity.5
Treatment options for obesity include non-surgical treatment
and bariatric surgery. The non-surgical treatment is usually a
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multicomponent approach comprising behavioural therapy,
dietary changes with the main aim of reducing energy intake,
increasing physical activity, and various pharmacotherapies.6
The most commonly used bariatric surgery techniques are
Roux-en-Y gastric bypass, sleeve gastrectomy, and laparoscopic
adjustable gastric banding.7-9 Current guidelines recommend
evaluation of bariatric surgery for individuals with a body mass
index >40 or >35 with serious comorbidities related to
obesity.8 10 A Cochrane review from 2009 suggested greater
body weight loss, improvement in the control of comorbidities,
and better quality of life in obese patients who underwent
bariatric surgery compared with non-surgical treatment for
obesity.11 However, the review included only a qualitative
summary of three randomised controlled trials.11 12 Since then
several further randomised controlled trials have been
completed. The present systematic review and meta-analysis
aims at comprehensively summarising and quantifying the
effects of bariatric surgery comparedwith non-surgical treatment
in randomised controlled trials on weight loss, cardiovascular
risk factors, adverse events, and quality of life in individuals
with a body mass index ≥30.
Methods
Eligibility criteria
Studies were eligible if they were randomised controlled trials
(≥6months’ follow-up); included individuals with a bodymass
index ≥30; investigated currently used laparoscopic or open
bariatric surgery techniques (Roux-en-Y gastric bypass,
adjustable gastric banding, sleeve gastrectomy, biliopancreatic
diversion, or biliopancreatic diversion with duodenal switch);
investigated as comparator non-surgical treatment for obesity
(diet, weight reducing drugs, behavioural therapy, or any
combination thereof); and reported changes in body weight;
body fat mass; fat-free mass; waist circumference; blood
pressure; fasting levels of plasma total cholesterol, high density
and low density lipoproteins, triglycerides, glycated
haemoglobin HbA1c, and glucose; quality of life from baseline
to the end of follow-up; remission of type 2 diabetes, metabolic
syndrome, or hypertension; reduction in the use of
antihypertensive, antidiabetic, or lipid lowering drugs; and
adverse events.
Information sources and searches
We aimed to identify all relevant studies regardless of language
or publication status. We searched Medline (via Pubmed),
Embase, and theCochrane Library from their inception to June
2013 (for search strategies see appendix tables 1 and 2 on
bmj.com). We also searched trial registries of ongoing trials
(appendix table 3). Additionally, we contacted authors to obtain
additional data.
Study selection
Two reviewers independently screened retrieved database files
and the full text of potentially eligible studies for relevance.
Disagreement was resolved by consensus.
Data collection and risk of bias assessment
Two reviewers abstracted data independently into a pilot tested,
data abstraction form on general study characteristics, baseline
characteristics of individuals, outcomes mentioned above, and
assessed risk of bias for each included study at the level of
selected outcomes.13 We assessed publication bias by creating
a funnel plot for the mean differences in body weight change.14
Disagreement was resolved by consensus.
Data synthesis and analysis
Relative risks (with 95% confidence intervals) were calculated
for dichotomous data, andmean differences were calculated for
continuous data. Statistical analyses were performed using
RevMan 5.1. Outcome measures were quantitatively
summarised, if possible, using a random effects model. For
some studies the mean change from baseline to end of follow-up
was calculated.
Missing standard deviations were derived from other statistics,
such as P values or confidence intervals if needed.15 When a P
value was reported as, for example, P≤0.001, P=0.001 was
assumed.13 Heterogeneity among combined study results was
assessed by Cochran’s Q test and by the degree of inconsistency
(I2).13 Furthermore, subgroup and sensitivity analyses were
performed.
In order to investigate the influence of missing data on the
pooled effect sizes for diabetes and metabolic syndrome
remission, we conducted both a complete case and a
conservative case scenario analysis. In the conservative case
scenario, we treated all patients with missing data in the
non-surgical treatment group as if they achieved remission and
those in the bariatric surgery group as if they did not. The terms
remission of type 2 diabetes or metabolic syndrome were used
as defined by study authors (appendix table 4).
Results
The study selection process is summarised in figure 1⇓. From
a total of 1988 records, 11 studies (n=796) were eligible and
included in the meta-analysis. A list of included studies with
the corresponding publications, and a table summarising ongoing
trials (n=18) is provided in appendix tables 3 and 5. Additional
data or information for risk of bias assessment were obtained
for the studies Mingrone 2012,16 Mingrone 2002,17 Schauer
2012,18 Ikramuddin 2013,19 and Reis 201020 by contacting the
study authors. Standard deviations were derived from the 95%
confidence intervals for O’Brien 201021 and Dixon 2012.22 We
imputed standard deviations for Mingrone 2002,17 O’Brien
2006,23 and Liang 201324 by taking themedian standard deviation
of the respective groups of the other studies, because no other
statistic was available.
General study characteristics
The 11 studies included were conducted in Australia (4), Italy
(2), Denmark (1), US (1), China (1), Brazil (1), and in the US
and Taiwan (1) (appendix table 6). Five studies included only
individuals with type 2 diabetes,17-19 24 25 three studies included
only individuals who had made serious attempts at weight loss
before,21-23 and one study included only individuals with
obstructive sleep apnoea.22Bariatric surgery was compared with
non-surgical treatment, which generally comprised alterations
in dietary intake, physical activity, behavioural or lifestyle
modification, and pharmacotherapy. Study groups are described
in appendix table 7. Only four studies17 19 21 22 quantitatively
reported restrictions in energy intake. In four studies18 19 22 25 the
same treatment for the non-surgical group was also offered to
the surgical groups, and in one study an extensive weight loss
programme was applied for four months before bariatric
surgery.20One study had a follow-up of 40 weeks,26 four studies
had a follow-up of one year,17-19 24 and all other studies had a
follow-up of two years. The studies comprised two three-arm
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studies and nine two-arm studies, with five of them evaluating
the effects of laparoscopic adjustable gastric banding,21-23 25 26
five evaluating Roux-en-Y gastric bypass,16 18-20 24 one evaluating
sleeve gastrectomy,18 and two evaluating biliopancreatic
diversion.16 17 Individuals’ baseline characteristics are presented
in table 1⇓. One study21 included adolescents (mean age range
16-17 years); the other studies were of adults (mean age range
37-51 years across studies). Mean bodymass index ranged from
30 to 52 across studies. One study reported only ranges of body
mass index (40-56) and age (40-56 years) at baseline.26
Risk of bias assessment
Results of the risk of bias assessment are presented in tables 2⇓
and 3⇓ and in more detail in appendix table 8. The sequence
generation for randomisation was adequate in all studies but
one.26 Concealment of group allocation was unclear in five
studies.21 22 24-26 In all studies, patients and healthcare providers
were not blinded. Data collectors, outcome adjudicators, and
data analysts were not blinded as far as outcomes relevant to
this review are concerned in two studies,18 20 blinded in three
studies,16 17 19 and unclear in the remaining six studies. In all
studies patients were analysed in the groups to which they were
randomised. In four studies not all individuals randomised were
finally analysed.16 21 23 24 Across studies, the percentage of
individuals not analysed ranged from 3% to 28% in the
non-surgical treatment group and from 1% to 14% in the
bariatric surgery group.
Missing continuous outcome data were not addressed
appropriately (either not addressed at all or use of baseline data
carried forward analysis) in four studies.21 23-25 Missing data on
diabetes remission were addressed in three of four studies
reporting on this outcome.16 18 25However, the reported risk ratio
was based on the complete data set. Missing data on metabolic
syndrome remission were not addressed in three of five
studies.21 23 25
All but three studies20 24 26 were free of selective reporting. In
two of the studies adverse events were poorly reported,20 24 and
the other study was only available as an abstract.26
Publication bias was assessed descriptively for the outcome of
body weight loss (appendix fig 1). Because of the limited
number of studies, publication bias was judged as unclear.
Outcomes
Body weight
Changes in body weight were pooled for 10 studies; one study24
reported only on body mass index. Individuals after bariatric
surgery lost more body weight (mean difference −26 kg (95%
confidence interval −31 to −21), P<0.001) than individuals after
non-surgical treatment (fig 2⇓). Heterogeneity among studies
was high (I2=95%). Excluding studies with ≤1 year of follow-up
did not change the effect size (mean difference −27 kg (−36 to
−18)) nor the degree of heterogeneity (I2=96%).
Subgroup analyses—Body weight loss was not significantly
different between adjustable gastric banding and other bariatric
surgery techniques combined (difference of the mean difference
−7 kg, P=0.29) (fig 2⇓), nor between adjustable gastric banding
and Roux-en-Y gastric bypass (difference of the changes in
mean difference −6 kg, P=0.230) (fig 3⇓). Individuals in trials
with a mean baseline body mass index ≥40 lost more body
weight than individuals in trials with a mean baseline bodymass
index <40 (difference of the mean difference −13 kg, P<0.001)
(appendix fig 2). Bodyweight loss was not significantly different
between surgically treated individuals who additionally received
the same treatment as the non-surgical treatment group
(difference of the changes in mean difference −6 kg, P=0.24)
and individuals after bariatric surgery who received a different
accompanying treatment (appendix fig 3). Across all subgroup
analyses, statistical heterogeneity remained high.
Waist circumference
Changes in waist circumference were available for six
studies.18 19 21-23 25 Waist circumference decreased more after
bariatric surgery than after non-surgical treatment (mean
difference −16 cm (−18 to −13), P<0.001). Heterogeneity was
moderate (fig 4⇓).
Fat-free mass and fat mass
Changes in fat-free mass and fat mass were pooled for two
studies.17 27 Individuals after bariatric surgery lost more fat-free
mass (mean difference −5 kg (−11 to −1), P=0.01) and more
fat mass (mean difference −18 kg (−31 to −5), P=0.001) than
after non-surgical treatment (appendix fig 4A and 4B).
Diabetes remission
The relative risk of type 2 diabetes remission was pooled for
four studies.16 18 24 25 All of them included only individuals with
type 2 diabetes at baseline. Different definitions for diabetes
remission were used, and one study24 did not report a definition
(appendix table 4). Based on the complete case analysis, the
relative risk to achieve diabetes remission was 22 times higher
(relative risk 22.1 (3.2 to 154.3), P=0.002) compared with
non-surgical treatment (fig 5⇓). Heterogeneity was high. Based
on the conservative case scenario, the relative risk to achieve
diabetes remission was five times higher (relative risk 5.3 (1.8
to 15.8), P=0.003) after bariatric surgery. Heterogeneity was
high (appendix fig 5).
Metabolic syndrome remission
The relative risk of metabolic syndrome remission was available
for five studies.18 21 23 25 28All studies included mixed populations
of individuals with and without metabolic syndrome (table 1⇓).
Three studies used the same definition for metabolic syndrome
remission, one definition was adapted to adolescents, and the
other study did not report on a definition (appendix table 4).
Based on the complete case analysis, the relative risk to achieve
metabolic syndrome remission was 2.4 times higher (relative
risk 2.4 (1.6 to 3.6), P<0.001) compared with non-surgical
treatment. Heterogeneity was moderate (fig 6⇓). Based on the
conservative case scenario, there was no significant difference
in metabolic syndrome remission between bariatric surgery and
non-surgical treatment (relative risk 1.5 (0.9 to 2.3), P=0.12).
Heterogeneity was high (appendix fig 6).
Hypertension remission
This was not addressed by any of the studies.
Blood pressure
The mean changes in systolic blood pressure were available for
seven studies16 18 19 21 24 25 28 and changes in diastolic blood
pressure for six studies.16 18 19 21 25 28 Changes in systolic (mean
difference −8.8 mm Hg (−26.2 to 8.5), P=0.32) and diastolic
(mean difference −0.4 mm Hg (−2.9 to 2.1), P=0.77) blood
pressure were not significantly different between bariatric
surgery and non-surgical treatment. Heterogeneity was high for
systolic and moderate for diastolic blood pressure (appendix
fig 7A and 7B).
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Triglyceride concentrations
The mean changes in triglyceride concentrations were available
for eight studies.16-19 21 24 25 28 Triglycerides decreased more after
bariatric surgery (mean difference −0.7 mmol/L (−1.0 to −0.4),
P<0.001) than after non-surgical treatment. Heterogeneity was
high (fig 7⇓).
Plasma cholesterol
Themean changes in total cholesterol concentration were pooled
for seven studies.16-19 24 25 28 Change of cholesterol was not
significantly different between bariatric surgery and non-surgical
treatment (mean difference −0.4 mmol/L (−0.8 to 0.00),
P=0.05). Heterogeneity was high (fig 8⇓).
Changes in high density lipoprotein cholesterol concentration
were available for eight studies.16-19 21 24 25 28 Concentration
increased more after bariatric surgery than after non-surgical
treatment (mean difference 0.21mmol/L (0.1 to 0.3), P<0.001).
Heterogeneity was high (fig 9⇓).
The mean changes in low density lipoprotein cholesterol
concentration were available for five studies.16-19 24 Changes in
concentration were not significantly different between the two
groups (mean difference −0.6 mmol/L (−1.2 to −0.01), P=0.06).
Heterogeneity was high (fig 10⇓).
Plasma glucose
Mean changes in fasting glucose levels were available for seven
studies.16-19 21 25 28 Glucose levels decreased more after bariatric
surgery than after non-surgical treatment (mean difference −1.5
mmol/L (−2.1 to −0.8), P<0.001). Heterogeneity was high (fig
11⇓. and appendix fig 9). Glucose levels decreased more after
Roux-en-Y gastric bypass, sleeve gastrectomy, or biliopancreatic
diversion than after adjustable gastric banding (test for subgroup
differences P<0.001) for all patients (fig 11⇓) as well as for
studies which included patients with diabetes only (appendix
fig 8).
Mean changes in glycated haemoglobin HbA1c were pooled for
the five studies including only individuals with type 2
diabetes.16 18 19 24 25 HbA1c decreased more after bariatric surgery
than after non-surgical treatment (mean difference −1.5% (−1.9
to −1.1), P<0.001). Heterogeneity was moderate (fig 12⇓).
Medication use
Medication use was reported by four studies.18 19 24 25 In Schauer
201218 the goal of medical management was to reach an HbA1c
≤6%, a blood pressure of ≤130/80 mm Hg, and a low density
lipoprotein cholesterol level of<2.6 mmol/L. In Dixon 200825
drug treatment was determined by an experienced diabetologist
on an individual basis. In Liang 201324 the aim was to reach an
HbA1c <7% and a blood pressure of ≤140/90 mm Hg. In
Ikramuddin 201319 the aim was to reach an HbA1c <7%, low
density lipoprotein cholesterol level<2.6 mmol/L, and a systolic
blood pressure of ≤130 mm Hg.
Ikramuddin 2013 reported the average change in antidiabetic,
antihypertensive, and lipid lowering drug use combined. The
group treated by Roux-en-Y gastric bypass used 3.0 (95%
confidence interval 2.3 to 3.6) fewer drugs than the non-surgical
treatment group at one year of follow-up.19 Schauer 2012
reported that the number of patients receiving antidiabetic drugs
decreased from 42 to 10 after Roux-en-Y gastric bypass (−76%)
and from 41 to 19 after sleeve gastrectomy (−54%), but did not
change after non-surgical treatment at one year of follow-up.18
Liang 2013 reported that oral hypoglycaemic agents and insulin
use were stopped in all patients after Roux-en-Y gastric bypass.24
Similarly, Dixon 2008 reported that the number of patients
receiving antidiabetic drugs decreased from 28 to three after
adjustable gastric banding (−89%) and from 26 to 18 after
non-surgical treatment (−18%) at two years of follow-up.25
Schauer 2012 reported, that the number of patients receiving
antihypertensive drugs decreased from 39 to 16 after Roux-en-Y
gastric bypass (−59%), from 33 to 13 after sleeve gastrectomy
(−61%), and from 31 to 30 (−3%) after non-surgical treatment.18
Similarly, Liang 2013 reported that antihypertensive drug use
decreased after Roux-en-Y gastric bypass and remained
unchanged after non-surgical treatment.24 In Dixon 2008, the
number of patients receiving antihypertensive drugs decreased
from 20 to six after adjustable gastric banding (−70%) but not
after non-surgical treatment.25
Schauer 2012 reported that the number of patients receiving
lipid lowering agents decreased from 43 to 13 after Roux-en-Y
gastric bypass (−70%) and from 38 to 19 after sleeve
gastrectomy (−50%), but increased from 34 to 36 after
non-surgical treatment (6%).18 Patients receiving lipid lowering
agents after adjustable gastric banding decreased from 12 to
four (−67%) and from eight to seven after non-surgical treatment
(−13%).25
Quality of life
Quality of life was reported in three studies. Two studies used
the SF-36 (Medical Outcomes Trust Short Form 36)
questionnaire. In one of these studies,22 three of eight domains
(physical role, general health, and vitality) improvedmore after
bariatric surgery, as did five of eight domains in the other study
(physical function, physical role, general health, energy, and
emotional role).23 In the third study,21 which included
adolescents, the Child Health Questionnaire was used. Here,
two of eight domains (general health and change in health)
improved more after bariatric surgery.
Adverse events
Adverse events are listed in appendix table 9. All but one study17
reported adverse events in the publication, but the missing data
were obtained on request. There were no perioperative deaths,
cardiovascular events, or deaths during follow-up. One
Roux-en-Y gastric bypass patient who developed a leak from
the jejuno-jejunostomy suffered anoxic brain injury, lower
extremity amputation, and long term disability. After bariatric
surgery, 21/261 (8%) individuals required reoperations (15/124
after adjustable gastric banding, 4/69 after Roux-en-Y gastric
bypass, 1/49 after sleeve gastrectomy, 1/19 after biliopancreatic
diversion). Three individuals developed hernia (1 after
Roux-en-Y gastric bypass, 1 after biliopancreatic diversion, 1
after adjustable gastric banding) and five developed pneumonia
(2 Roux-en-Y gastric bypass, 3 adjustable gastric banding).
Other adverse events occurred after bariatric surgery as well as
after non-surgical treatment: 29/194 (15%) developed iron
deficiency anaemia after bariatric surgery other than adjustable
gastric banding (21/126 Roux-en-Y gastric bypass, 6/49 sleeve
gastrectomy, 2/19 biliopancreatic diversion) and 3/169 (2%)
after non-surgical treatment. Cholecystitis requiring
cholecystectomy occurred in 4/261 (1.5%) of surgically and in
5/169 (3%) of non-surgically treated individuals. Depression
developed in 1/261 of surgically treated and in 1/55 of
non-surgically treated individuals.
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This systematic review and meta-analysis demonstrates that
bariatric surgery is more efficient than non-surgical treatment
for obesity for up to two years of follow-up. Bariatric surgery
led to greater body weight loss, higher rates of remission of type
2 diabetes and metabolic syndrome, greater improvements in
quality of life, and greater reductions in use of antidiabetic,
antihypertensive, and lipid lowering drugs. Furthermore, waist
circumference and fasting levels of plasma glucose, HbA1c, and
triglycerides decreased more, and high density lipoprotein
cholesterol levels increased more, after bariatric surgery. There
was no significant difference between bariatric surgery and
non-surgical treatment for changes in blood pressure and levels
of total or low density lipoprotein cholesterol (though some
studies reported concomitant reductions in drug use for these
conditions). There were no perioperative deaths or
cardiovascular events reported during follow-up. The most
common adverse events after bariatric surgery were iron
deficiency anaemia for individuals undergoing malabsorptive
bariatric surgery (15%) and reoperations (8%).
Strengths and limitations of study
The strength of this study is its comprehensive approach to
identify all randomised controlled trials comparing bariatric
surgery with non-surgical treatment for obesity. It quantitatively
summarises the currently available evidence on a large spectrum
of health outcomes. Our results proved to be robust across
various sensitivity analyses and across most subgroups.
We conducted two analyses for remission rates of type 2 diabetes
and metabolic syndrome: a complete case and a conservative
case scenario. Both types of analysis favoured bariatric surgery
over non-surgical treatment concerning remission of type 2
diabetes, but the assumptions made about missing data affected
the effect size substantially. Concerning metabolic syndrome
remission, only the complete case analysis favoured bariatric
surgery.
Though the differences in body weight loss might explain some
of the greater improvements in diabetes remission after bariatric
surgery compared with non-surgical treatment, changes in the
gastrointestinal anatomy, gut hormones, and regulatory factors
of energy homeostasis may be the primary mediators.29 30 This
is consistent with the findings that Roux-en-Y gastric bypass
and biliopancreatic diversion caused diabetes remission within
days to weeks after surgery, before substantial weight loss
occurred.31 32 Whether different definitions used for type 2
diabetes remission (appendix table 4) had an effect was not
investigated because of the limited number of studies identified.
However, investigators of future trials are encouraged to use a
standard definition for diabetes remission.33
Our study has several limitations. Summary measures of effect
sizes are based on only 11 studies or fewer depending on
outcome. Furthermore, the methodological quality of five of
these studies suffered from unclear allocation concealment. The
risk for attrition bias was high in four studies, and attrition was
always higher in the non-surgical treatment group. Under the
assumption that patients in the non-surgical treatment group
with complete data did better than those with missing data, our
results seem to represent a conservative estimate of the benefits
of bariatric surgery over non-surgical treatment. As far as body
weight loss is concerned, the non-surgical treatment groupmight
have been prone to do worse, because it can be assumed that
previous weight loss attempts by similar means (such as food
restriction) occurred in participants of all studies. Three of the
included trials21-23 explicitly mentioned that all included
individuals were required to have made serious attempts to lose
weight before entering the study. Thus, the results presented in
our meta-analysis may not apply to individuals without prior
weight loss attempts.
All included trials were relatively small, conducted in centres
of excellence for bariatric surgery, and limited to a maximum
of two years of follow-up. Thus adverse events reported in this
meta-analysis may underestimate rates in less specialised centres
or in larger trials with broader patient populations, and no
conclusions can be drawn for adverse events in the longer term.
In addition, it may underestimate rates in obese patients with
multiple or severe comorbidities, because such patients were
excluded in most of the included trials. It must also be kept in
mind that individuals after bariatric surgery must adhere to
lifelong micronutrient supplementation after malabsorptive
bariatric surgery and are often advised to avoid commonly used
drugs such as non-steroidal anti-inflammatory drugs.
Furthermore, harms are often poorly reported in surgical trials
and randomised controlled trials in general.34 35 In a
meta-analysis including 14 studies (1 randomised controlled
trial and 13 prospective studies) comparing Roux-en-Y gastric
bypass with adjustable gastric banding, perioperative mortality
was less than 0.5% for both procedures.36 Reported long term
reoperation rates (16% after Roux-en-Y gastric bypass and 24%
after adjustable gastric banding) were two to three times higher
than in our meta-analysis. In the observational SOS study,37
perioperative mortality for vertical banded gastroplasty, gastric
banding, or gastric bypass was 0.25% and reoperation rate was
3%.37
We do not have information from randomised controlled trials
on body weight in the longer term. Large prospective
observational studies showed that individuals regained about
7% of their lost body weight between two and 10 years after
Roux-en-Y gastric bypass.37 38 In contrast, regain of lost body
weight in a large trial using lifestyle modification was about
40% between one and four years of follow-up.39
Our meta-analysis could also not investigate the effect of
bariatric surgery on cardiovascular morbidity and mortality. A
meta-analysis including eight non-randomised trials with 44 022
participants and a mean follow-up of 7.5 years showed a
reduction in cardiovascular mortality (odds ratio 0.58 (95%
confidence interval 0.46 to 0.73)) and overall mortality (odds
ratio 0.7 (0.59 to 0.84)) after bariatric surgery compared with
non-surgical controls.40 Thus, the greater improvements in
cardiovascular risk factors after bariatric surgery may translate
to reduced cardiovascular morbidity and mortality.
We think that, for some meta-analyses, I2 was misleadingly
high. Conceptually, I2 represents the ratio of the variability
between studies to the variability within studies and is
independent from the number of included studies. When the
variability within studies is small—represented by narrow
confidence intervals—the variability between studies can also
be small and the I2 nevertheless high and inflated.41 42 This is
shown vividly, for example, by the weight outcome (fig 2⇓).
Here, the intuitive, and correct, interpretation of the results is
that they consistently show a large effect. The high I2 reflects
the uncertainty that remains between the lowest weight loss
(∼21 kg) and the largest (∼31 kg), but the results leave us
confident that the true effect lies between these values, and the
pooled effect (∼26 kg) provides the best single estimate.
In subgroup analyses comparing adjustable gastric banding with
other bariatric surgery techniques (Roux-en-Y gastric bypass,
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sleeve gastrectomy, and biliopancreatic diversion combined) or
with Roux-en-Y gastric bypass, there was no significant
difference in body weight loss. However, the power of our
subgroup analysis to detect differences between adjustable
gastric banding and other bariatric surgery techniques was
limited by the small number of participants. Furthermore,
comparisons are limited to between-study comparisons. In a
recent meta-analysis including five randomised controlled trials
comparing adjustable gastric banding directly with other
bariatric surgery techniques, adjustable gastric banding was
associated with less body weight loss.43
The results of this meta-analysis apply to a general population
of obese individuals below the age of 60 years with a body mass
index ≥30. In the included studies, the age ranged from 16 to
60 years, the proportion of females ranged from 0 to 88%, and
the body mass index at baseline from 30 to ≥55 (except for two
studies18 24). No information was available on ethnicities, except
for one study.19Results might be different for specific subgroups.
The limited number of studies prevented investigations of
differential effects due to age or sex. When studies were
stratified by mean baseline body mass index, individuals in
trials with a body mass index ≥40 lost more body weight after
bariatric surgery than individuals in trials with a body mass
index <40.
Comparison with other studies
To our knowledge this is the first meta-analysis of randomised
controlled trials directly comparing bariatric surgery with
non-surgical treatment for obesity. Our results are supported by
two systematic reviews. A Cochrane review from 2009 included
three randomised controlled trials and three prospective cohort
studies. It showed greater body weight loss and greater
improvements in cardiovascular risk factors and quality of life
after bariatric surgery compared with non-surgical treatment.11
The other systematic review from 2013 included three
randomised controlled trials and two prospective cohort studies
and had similar results.44 Neither review performed a
meta-analysis. A network meta-analysis from 2011 pooled
changes in body mass index but did not pool changes in body
weight.12 Unlike our meta-analysis, greater improvements in
other health outcomes after bariatric surgery were not found.
This may be because the network analysis was based on only
one direct comparison of bariatric surgery (biliopancreatic
diversion) with non-surgical treatment.12
Conclusions
This meta-analysis provides comprehensive evidence that,
compared with non-surgical treatment of obesity, bariatric
surgery leads to greater body weight loss and higher remission
rates of type 2 diabetes and metabolic syndrome. The most
common adverse events after bariatric surgery were iron
deficiency anaemia (malabsorptive bariatric surgery) and
reoperations. Only few studies reported on quality of life, which
suggested greater improvements in surgically treated individuals.
Results are limited to two years’ follow-up and based on a small
number of studies and individuals. The evidence beyond two
years of follow-up, in particular on adverse events,
cardiovascular diseases, and mortality remains unclear and calls
for further research on the topic.
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AGB=adjustable gastric banding; BMI=body mass index, BPD=biliopancreatic diversion, NR=not reported, RYGB=Roux-en-Y gastric bypass.
*In three-arm studies Mingrone 2012 and Schauer 2012 the two bariatric surgery groups were combined, and in Liang 2013 the two non-surgical groups were
combined.
†This is the time point before RYGB and 4 months after extensive weight-loss programme in the bariatric surgery group.
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NA=Not applicable, because outcome was not addressed in the study.
*With regard to body weight loss.
†For data in the publication yes, but not for data additionally obtained by contacting study authors.
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Figures
Fig 1 Results on information search. (*Relevant bariatric surgery techniques were Roux-en-Y gastric bypass, adjustable
gastric banding, sleeve gastrectomy, and biliopancreatic diversion with or without duodenal switch)
Fig 2Mean change in body weight (kg) after bariatric surgery versus non-surgical treatment (control) for obesity. Subgroup
analysis was done for the studies that used adjustable gastric banding versus other bariatric surgery techniques. (Differences
in mean change in body weight calculated by inverse variance statistical method of random effects model)
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Fig 3 Mean change in body weight (kg) after adjustable gastric banding or Roux-en-Y gastric bypass versus non-surgical
treatment (control) for obesity. Subgroup analysis was done for the studies that used adjustable gastric banding versus
Roux-en-Y gastric bypass. (Differences in mean change in body weight calculated by inverse variance statistical method
of random effects model)
Fig 4 Mean change in (cm) after bariatric surgery versus non-surgical treatment (control) for obesity. Subgroup analysis
was done for the studies that used adjustable gastric banding versus other bariatric surgery techniques. (Differences in
mean change in waist circumference calculated by inverse variance statistical method of random effects model)
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Fig 5 Type 2 diabetes remission after bariatric surgery versus non-surgical treatment (control) for obesity. Subgroup analysis
was done for the studies that used adjustable gastric banding versus other bariatric surgery techniques. (Risk ratios
calculated by Mantel-Haenzel statistical method of a random effects model; missing data were not addressed (complete
case analysis))
Fig 6 Metabolic syndrome remission after bariatric surgery versus non-surgical treatment (control) for obesity. Subgroup
analysis was done for the studies that used adjustable gastric banding versus other bariatric surgery techniques. (Risk
ratios calculated by Mantel-Haenzel statistical method of a random effects model; missing data were not addressed (complete
case analysis))
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Fig 7 Change in plasma triglyceride concentrations (mmol/L) after bariatric surgery versus non-surgical treatment (control)
for obesity. Subgroup analysis was done for the studies that used adjustable gastric banding versus other bariatric surgery
techniques. (A conversion factor of 0.01129 used to convert values from mg/dL to mmol/L. Differences in mean change in
triglyceride concentration calculated by inverse variance statistical method of random effects model)
Fig 8 Change in plasma total cholesterol concentration (mmol/L) after bariatric surgery versus non-surgical treatment
(control) for obesity. Subgroup analysis was done for the studies that used adjustable gastric banding versus other bariatric
surgery techniques. (A conversion factor of 0.02586 was used to convert values frommg/dL to mmol/L. Differences in mean
change in cholesterol concentration calculated by inverse variance statistical method of random effects model)
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Fig 9 Change in high density lipoprotein cholesterol concentrations (mmol/L) after bariatric surgery versus non-surgical
treatment (control) for obesity. Subgroup analysis was done for the studies that used adjustable gastric banding versus
other bariatric surgery techniques. (A conversion factor of 0.02586 was used to convert values from mg/dL to mmol/L.
Differences in mean change in concentration calculated by inverse variance statistical method of random effects model)
Fig 10 Change in low density lipoprotein cholesterol concentrations (mmol/L) after bariatric surgery versus non-surgical
treatment (control) for obesity. (A conversion factor of 0.02586 was used to convert values frommg/dL to mmol/L. Differences
in mean change in concentration calculated by inverse variance statistical method of random effects model)
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Fig 11 Change in plasma fasting glucose concentrations (mmol/L) after bariatric surgery versus non-surgical treatment
(control) for obesity. Subgroup analysis was done for the studies that used adjustable gastric banding versus other bariatric
surgery techniques. (Differences in mean change in concentration calculated by inverse variance statistical method of
random effects model)
Fig 12Change in glycated haemoglobin HbA1c levels (% points) after bariatric surgery versus non-surgical treatment (control)
for obesity. The mean change in HbA1c was pooled for the studies that included diabetic participants only. Subgroup analysis
was done for the studies that used adjustable gastric banding versus other bariatric surgery techniques. (Differences in
mean change in concentration calculated by inverse variance statistical method of random effects model)
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f5934 doi: 10.1136/bmj.f5934 (Published 22 October 2013) Page 16 of 16
RESEARCH
